Lorenzo Sabatelli
Rue Docteur Yersin 12
Morges, VD 1110, Switzerland
Morges, VD 1110, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Healthcare Resource Utilization and Economic Burden Across Clinical Phenotypes of Moderate-to-Severe Atopic Dermatitis in United States Dermatology Facilities.
Journal: Dermatology and therapy
Published: October 10, 2025
Burden of Atopic Dermatitis in Patients Initiating Systemic Therapies in the United States.
Journal: Advances in therapy
Published: April 30, 2025
Combined impact of lesion and itch severity on initiation of biologic treatment in patients with moderate or severe atopic dermatitis from specialty dermatology facilities in the United States.
Journal: Journal of the American Academy of Dermatology
Published: March 30, 2025
Economic and comorbidity burden of prurigo nodularis in the United States between 2017 and 2022: A retrospective matched cohort study.
Journal: Journal of the American Academy of Dermatology
Published: December 25, 2024
Treatment Patterns and Clinical Outcomes of Patients with Moderate to Severe Acute Graft-Versus-Host Disease: A Multicenter Chart Review Study.
Journal: Hematology reports
Published: December 28, 2023
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.
Journal: Annals of hematology
Published: July 11, 2023
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.
Journal: Advances in therapy
Published: January 25, 2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Journal: Annals of hematology
Published: May 25, 2022
Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Journal: Advances in therapy
Published: January 03, 2022
Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data study.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: August 31, 2021
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
Journal: Journal of medical economics
Published: August 10, 2018
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
Journal: Journal of medical economics
Published: February 27, 2018
Last Updated: 09/26/2026